Would you consider adding durvalumab to second-line chemotherapy for cholangiocarcinoma which progressed on gem/cis alone?

Yes. Data is needed, however, a scaffold approach maintaining durvalumab and adding different chemotherapies like NIFTY or FOLFOX as walls to the building frame of immunotherapy is appropriate and justified.